SCHEMBL975684

SCHEMBL975684

CCO[Si](CCCNc1nc(N)nc(N(CCC[Si](OCC)(OCC)OCC)CCC[Si](OCC)(OCC)OCC)n1)(OCC)OCC

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC29A1 Q99808 3/20 0.34
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
NPC1 O15118 1/20 0.33
LMNA P02545 1/20 0.33
HSP90AA1 P07900 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
MAPK1 P28482 1/20 0.33
CASP3 P42574 1/20 0.33
HTT P42858 1/20 0.33
CDK9 P50750 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
SENP7 Q9BQF6 1/20 0.33
TLR8 Q9NR97 1/20 0.30
CA1 P00915 1/20 0.30
CA2 P00918 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23327153 0.93 SLC29A1 (0.33) SLC29A1ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL978050 0.87 HTR7 (0.34) SLC29A1ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL20740706 0.85 SLC29A1 (0.39) SLC29A1SMN1; SMN2KMT2ACA1CA2
SCHEMBL978140 0.85 SLC29A1 (0.38) SLC29A1ALDH1A1SMN1; SMN2KDM4EMEN1
SCHEMBL25249412 0.85 TLR8 (0.36) ALDH1A1SMN1; SMN2KDM4EMEN1NPC1
SCHEMBL16628414 0.84 CYP1A2 (0.33) SLC29A1SMN1; SMN2CA1CA2CA9
SCHEMBL20740721 0.82 DNM2 (0.41) SLC29A1SMN1; SMN2MAPTHTTKMT2A
SCHEMBL25293981 0.81 HTR7 (0.38) ALDH1A1SMN1; SMN2KDM4EMEN1NPC1
SCHEMBL25285855 0.79 HTR7 (0.39) ALDH1A1SMN1; SMN2KDM4EMEN1NPC1
SCHEMBL25243268 0.79 HTR7 (0.39) ALDH1A1SMN1; SMN2KDM4EMEN1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2289898-B1 Melamine-functional organosilicon compound and making method SHINETSU CHEMICAL CO (JP) 2017-05-03 EP disclosed
US-8263766-B2 Melamine-functional organosilicon compound and making method SHIN-ETSU CHEMICAL CO., LTD. (JP) 2012-09-11 US disclosed
EP-2289898-A1 Melamine-Functional organosilicon compound and making method Shin-Etsu Chemical Co., Ltd. (JP) 2011-03-02 EP disclosed
US-20110003989-A1 MELAMINE-FUNCTIONAL ORGANOSILICON COMPOUND AND MAKING METHOD SHIN-ETSU CHEMICAL CO., LTD. (JP) 2011-01-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003989-A1 MELAMINE-FUNCTIONAL ORGANOSILICON COMPOUND AND MAKING METHOD MEN1, MSH6, PRMT6 SLC29A1 671/4885ALDH1A1 3030/4885SMN1; SMN2 823/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.